Osilodrostat provides sustained clinical benefits and improves health-related quality of life in patients with Cushing's disease: **Results from the Phase III** LINC 4 study

*Richard A Feelders,¹ *Mônica Gadelha,² *Marie Bex,³ *Przemysław Witek,⁴ *Zhanna Belaya,⁵ *Yerong Yu,⁶ *Adina F Turcu,⁷ *Anthony P Heaney,⁸ *Richard J Auchus,⁷ *Andrea Piacentini,⁹ *Alberto M Pedroncelli,¹⁰ *Peter J Snyder¹¹

erdam, Netherlands; ²Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ³University Hospital um; ⁴Medical University of Warsaw, Warsaw, Poland; ⁵Endocrinology Research Centre, Moscow, Russia; ⁶West China Hospital of Sichuan University, Chengdu, China; ⁷University of Michigan, Ann Arbor, MI, USA; ⁸University of California, Los Angeles, CA, USA; ⁹Recordati SpA, Milan, Italy; ¹⁰Recordati AG, Basel, Switzerland; ¹¹University of Pennsylvania, Philadelphia, PA, USA

Introduction

- As a consequence of chronic hypercortisolism, Cushing's disease is associated with cardiovascular morbidity and mortality, as well as impaired QoL¹
- Osilodrostat, a potent oral 11β -hydroxylase inhibitor, normalized mUFC and improved clinical parameters of hypercortisolism and QoL during the 48-week core phase of the Phase III LINC 4 study (NCT02697734)²
- We report here the long-term effects of osilodrostat on cardiovascular and metabolic-related parameters, physical manifestations of hypercortisolism, and QoL following an optional extension phase to LINC 4

CONCLUSIONS

- Improvements in cardiovascular and metabolic-related parameters that occurred during the core phase were maintained during long-term osilodrostat treatment, including reductions in blood pressure, glycemic parameters, weight and waist circumference, and total cholesterol
- Physical manifestations of hypercortisolism improved or remained stable from baseline to week 48 and end of treatment in most patients
- Improvements in patient-reported outcomes, such as CushingQoL and BDI-II scores, that were observed during the core phase continued during the extension
- Osilodrostat is an effective and well-tolerated long-term treatment that may alleviate disease burden and improve QoL for many patients with **Cushing's disease**

Acknowledgments

We thank Catherine Risebro and Beth Harrahill, Mudskipper Business Limited (funded by Recordati AG), for providing medical editorial assistance, as well as the site investigators, study coordinators and patients who participated in the trials

Disclosures

This study was sponsored by Novartis Pharma AG; as of July 12, 2019, osilodrostat is an asset of Recordati AG

*Potential conflict of interest may exist. Refer to the Meeting App

References

- I. Feelders et al. Eur J Endocrinol 2012;167:311–26
- 2. Gadelha M et al. J Clin Endocrinol Metab 2022; doi: 10.1210/clinem/dgac178
- 3. Webb SM et al. Eur J Endocrinol 2008;158:623–30
- 4. Beck AT et al. J Pers Assess 1996;67:588–97

Abbreviations

bid, twice daily; BDI-II, Beck Depression Inventory II; BL, baseline; CI, confidence interval; CushingQoL, Cushing's Quality of Life; DBP, diastolic blood pressure; EOT, end of treatment; FPG, fasting plasma glucose; HbA_{1c}, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; mUFC, mean urinary free cortisol; QoL, quality of life; QR, quick response; SBP, systolic blood pressure; SD, standard deviation; UFC, urinary free cortisol



Methods

LINC 4: Phase III study with an initial 12-week, double-blind, randomized, placebo-controlled period followed by open-label treatment until week 48, and an optional extension phase

					73 enrolled2:1 to osilodrostat or matching placebo*						
	Double blind Open label				Period 1 0–12 weeks				12		
								0		tat 2 mg ery 3 wee	
	Weight, wai	st circumferenc	ce, blood pressure	1 1 9	2	5 I	8 I	12	14		
	Glycemic and lipid parameter		nd lipid parameters	1			8 I	12	14 I	20 2	
		V° Physi	Physical manifestation	3				12		2	
				1	2	5	8	12	Every 14	/ 3 weeks 2	
		CushingQoL	and BDI-II scores)							

Results

4.6 (3.7–9.2) mg/day



Median (range) osilodrostat exposure: 87.1 (2–127) weeks


Median (IQR) average osilodrostat dose:





98.6% (n=72/73) of patients received ≥ 1 concomitant medication during the study


mUFC was rapidly normalized and sustained during long-term osilodrostat treatment. See poster RC7.6 for full efficacy and safety results following completion of the LINC 4 extension


1. Improvements in cardiovascular and metabolic-related parameters observed at week 48 were maintained during long-term osilodrostat treatment











 Scan QR code for data on LDL cholesterol, HDL cholesterol and triglycerides

Shaded areas represent results during the core phase. n is the number of patients with an evaluable assessment at both baseline and the later time point (ie weeks 48, 72, 96 or end of treatment [EOT])

*Dose increases (starting dose: 2 mg bid), were permitted every 3 weeks to normalize mUFC (maximum dose: 20 mg bid during period 1, 30 mg bid during period 2 and optional extension); dose decreases were permitted at any time for tolerability; †A protocol amendment was implemented in December 2019 that specified that the maximum duration of osilodrostat treatment was 96 weeks; however, at the time of the protocol amendment, some patients had already completed >96 weeks of treatment. The protocol amendment specified that patients enrolled in the optional extension phase were asked to come for an EOT visit within 4 weeks after amendment approval at their site, or by week 96, whichever occurred first. Patients who were still receiving clinical benefit were eligible to join a separate long-term follow-up study (NCT03606408); [‡]Patients on <2 mg bid at week 12 were restarted on the same dose

 Physical manifestations of hypercortisolism were assessed locally using frontal and lateral images of the shoulders up and frontal and dorsal images of the trunk; physical manifestations were rated on a semi-quantitative scale: 0=absent; 1=mild; 2=moderate; 3=severe

Results

2. Physical manifestations of hypercortisolism improved or remained stable from baseline to week 48 and end of treatment in most patients, with few patients experiencing worsening features

Week 48

Hirsutism (f

Supraclavic Proximal mus


End of trea

Hirsutism (fe

Supraclavic Proximal mus

n is the number of patients with an evaluable assessment at both baseline and the later time point (ie week 48 or end of treatment)

• Scan QR code for data on severity of physical manifestations of hypercortisolism at baseline



n is the number of patients with an evaluable assessment at both baseline and the later time point (ie week 48 or the extension end of treatment [EOT] visit). Dotted line indicates the distribution-based minimal important difference (MID) corresponding to a 10.1-point change from baseline for CushingQoL³ and a 17.5% reduction in scores from baseline for BDI-II⁴

emales only), n=48 Striae, n=59		75. 74.						16.	25.4	8.3	
cular fat pad, n=61		45.	.9				52.5			1.6	
orsal fat pad, n=60		43.	.3				50.0			6.7	
scle atrophy, n=61		62.	.3				29.5			8.2	
ntral obesity, n=61		50.	.8				41.0			8.2	
Ecchymoses, n=60		76	76.7					20.0	3.3		
atment	10	20	30	40	50	60	70	80	90	100	
Facial rubor, n=48		45	.8				47.9			6.3	
emales only), n=38			60.5				28	3.9		10.5	;
Striae, n=46			71.7				26.1		2.2		
cular fat pad, n=49		34.	.7				65.3				
orsal fat pad, n=48		31.	.3				58.3			10.4	ł
scle atrophy, n=49		61.	.2				32.7			6.1	
ntral obesity, n=49		36.	.7				55.1			8.2	
Ecchymoses, n=48		79.	.2						20.8		
F O	10	20	30	40	50	60	70	80	90	100	
				Proporti	on of pat	ients (%)					

3. Improvements in patient-reported outcomes (CushingQoL and BDI-II scores) during the core phase were maintained during long-term osilodrostat treatment